Key statistics
Short selling activityProvided by S&P Global Market Intelligence
Open | -- |
---|---|
High | 1,238.26 |
Low | 1,238.26 |
Bid | -- |
Offer | -- |
Previous close | 1,228.42 |
Average volume | 0.00 |
---|---|
Shares outstanding | 54.07m |
Free float | 50.62m |
P/E (TTM) | -- |
Market cap | 3.21bn USD |
EPS (TTM) | -1.76 USD |
Data delayed at least 20 minutes, as of Mar 07 2025.
More ▼
- PROCEPT BioRobotics® Reports Fourth Quarter and Full Year 2024 Results
- PROCEPT BioRobotics® to Report Fourth Quarter 2024 Financial Results on February 25, 2025 and Attend the TD Cowen 45th Annual Healthcare Conference and the 2025 Leerink Partners Healthcare Conference
- PROCEPT BioRobotics to Present at Upcoming 36th Annual Piper Sandler Healthcare Conference on December 4, 2024
- PROCEPT BioRobotics Corporation Announces Pricing of Offering of Common Stock
- PROCEPT BioRobotics Corporation Announces Proposed Offering of Common Stock
- PROCEPT BioRobotics® Reports Third Quarter 2024 Financial Results and Increases 2024 Revenue and Adjusted EBITDA Guidance
- PROCEPT BioRobotics to Report Third Quarter 2024 Financial Results on October 28, 2024
- PROCEPT BioRobotics Received U.S. FDA Approval to Initiate Pivotal Randomized Clinical Study for Prostate Cancer
- PROCEPT BioRobotics to Present at Upcoming 2024 Wells Fargo Healthcare Conference on September 4, 2024
- PROCEPT BioRobotics Announces FDA Clearance of the HYDROS™ Robotic System, the Next-Generation, AI-Powered Platform for Aquablation® Therapy
More ▼